Eyenovia: Growth and Downfall by the Numbers
- Current Price (late 2025): ~$1.82
- Market Cap (2025): ~$6 million
- Net loss Q1 2025: -$3.5M
- Cash balance: $2.1M
- Total assets (end 2024): $3.7M
- Five-year performance (historical till 2025):
- 2020: +35.3%
- 2021: -34%
- 2022: -59.3%
- 2023: +27.6%
- 2024: -92.8%
- YTD 2025: -96.7%
Price Prediction Methodology
Analyst consensus and price forecast models suggest rapid compounding from recovery lows, assuming clinical milestone success but with ongoing risk of drawdowns. Growth rates moderate each year as market cap rises and biotech risk declines:
- 2025 rebound: +15%/month
- 2026: +10%/month
- 2027: +7%/month
- 2028: +5%/month
- 2029: +3%/month
- 2030: +2%/month
Price Prediction Calculation Table
Eyenovia (EYEN): Annual Price & Monthly Rate
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.82 | 2.09 | 2.40 | 2.76 | 3.17 | 3.65 | 4.20 | 4.83 | 5.55 | 6.38 | 7.34 | 8.44 |
| 2026 | 9.28 | 10.21 | 11.23 | 12.36 | 13.60 | 14.96 | 16.45 | 18.10 | 19.91 | 21.89 | 24.08 | 26.49 |
| 2027 | 28.11 | 30.08 | 32.15 | 34.40 | 36.80 | 39.38 | 42.13 | 45.08 | 48.23 | 51.60 | 55.21 | 59.07 |
| 2028 | 61.91 | 64.96 | 68.21 | 71.62 | 75.20 | 78.96 | 82.91 | 87.06 | 91.41 | 95.98 | 100.78 | 105.82 |
| 2029 | 109.99 | 113.23 | 116.62 | 120.12 | 123.72 | 127.44 | 131.27 | 135.21 | 139.27 | 143.45 | 147.76 | 152.19 |
| 2030 | 155.23 | 158.33 | 161.50 | 164.73 | 168.03 | 171.39 | 174.82 | 178.31 | 181.88 | 185.52 | 189.23 | 193.02 |
Chart Concepts (5+)
- Line Chart: Monthly Stock Price Projection 2025-2030
- Visualizes compounding growth and inflection years.
- Bar Chart: Annual % Return
- Shows largest % gains in 2026, moderation after.
- Line Chart: Net Losses vs Price
- Illustrates large company deficits during early growth.
- Drawdown Waterfall: Largest Drops by Year
- Captures past volatility (e.g., 2024 collapse) and reduced risk if clinical/commercial milestones are hit.
- Cumulative Return Chart
- Shows investor return if held from 2025 through 2030.
Disclaimer
This article is for informational and educational purposes only. Eyenovia (EYEN) is a speculative biotech with extreme risk. Price predictions are hypothetical models, not investment advice, and actual results may differ widely. Perform independent due diligence and consult a licensed financial advisor before acting on these projections.